Cargando…
P785: SIX-MONTH CROVALIMAB EXTENSION IN THE PHASE 3 COMMODORE 3 STUDY: UPDATED EFFICACY AND SAFETY RESULTS IN COMPLEMENT INHIBITOR-NAIVE PATIENTS (PTS) WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Autores principales: | Liu, Hui, Xia, Linghui, Weng, Jianyu, Zhang, Fengkui, He, Chuan, Gao, Sujun, Jia, Jinsong, Chang, Alice, LI, Wenjin, Sreckovic, Sasha, Shi, Dayu, Zhang, Zilu, Fu, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430678/ http://dx.doi.org/10.1097/01.HS9.0000970044.12879.03 |
Ejemplares similares
-
S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS
por: Röth, Alexander, et al.
Publicado: (2023) -
S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Scheinberg, Phillip, et al.
Publicado: (2023) -
Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022) -
Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Burns, Ethan, et al.
Publicado: (2019) -
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
por: Lobry, Camille, et al.
Publicado: (2019)